Novo Nordisk A/S (NONOF)
USD 69.9
(6.72%)
USD 69.9
(6.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 93.92 Billion DKK | 27.44% |
| 2022 | 73.69 Billion DKK | 25.98% |
| 2021 | 58.49 Billion DKK | 12.74% |
| 2020 | 51.88 Billion DKK | 4.93% |
| 2019 | 49.45 Billion DKK | 5.29% |
| 2018 | 46.96 Billion DKK | 4.14% |
| 2017 | 45.09 Billion DKK | -2.31% |
| 2016 | 46.16 Billion DKK | 9.15% |
| 2015 | 42.29 Billion DKK | 6.4% |
| 2014 | 39.75 Billion DKK | 4.78% |
| 2013 | 37.93 Billion DKK | 8.13% |
| 2012 | 35.08 Billion DKK | 10.07% |
| 2011 | 31.87 Billion DKK | 1.14% |
| 2010 | 31.51 Billion DKK | 21.0% |
| 2009 | 26.04 Billion DKK | 12.64% |
| 2008 | 23.12 Billion DKK | -0.0% |
| 2007 | 23.12 Billion DKK | 15.38% |
| 2006 | 20.04 Billion DKK | 21.68% |
| 2005 | 16.47 Billion DKK | 16.84% |
| 2004 | 14.09 Billion DKK | 10.54% |
| 2003 | 12.75 Billion DKK | 1.58% |
| 2002 | 12.55 Billion DKK | 3.3% |
| 2001 | 12.15 Billion DKK | -0.3% |
| 2000 | 12.19 Billion DKK | -0.71% |
| 1999 | 12.27 Billion DKK | 7.19% |
| 1998 | 11.45 Billion DKK | 15.39% |
| 1997 | 9.92 Billion DKK | 13.38% |
| 1996 | 8.75 Billion DKK | 9.31% |
| 1995 | 8.01 Billion DKK | 2.12% |
| 1994 | 7.84 Billion DKK | 63.63% |
| 1993 | 4.79 Billion DKK | -31.38% |
| 1992 | 6.98 Billion DKK | 92.43% |
| 1991 | 3.63 Billion DKK | 15.09% |
| 1990 | 3.15 Billion DKK | 12.48% |
| 1989 | 2.8 Billion DKK | 41.85% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 23.01 Billion DKK | -20.85% |
| 2024 Q2 | 32.25 Billion DKK | 38.37% |
| 2023 FY | 93.92 Billion DKK | 27.44% |
| 2023 Q3 | 22.1 Billion DKK | -2.0% |
| 2023 Q4 | 29.08 Billion DKK | 31.57% |
| 2023 Q1 | 20.17 Billion DKK | -11.28% |
| 2023 Q2 | 22.55 Billion DKK | 11.79% |
| 2022 Q1 | 15.96 Billion DKK | -13.5% |
| 2022 Q3 | 18.18 Billion DKK | 8.19% |
| 2022 FY | 73.69 Billion DKK | 25.98% |
| 2022 Q2 | 16.8 Billion DKK | 5.25% |
| 2022 Q4 | 22.74 Billion DKK | 25.09% |
| 2021 Q3 | 14.31 Billion DKK | 12.58% |
| 2021 Q4 | 18.45 Billion DKK | 28.95% |
| 2021 Q1 | 13.01 Billion DKK | -15.19% |
| 2021 Q2 | 12.71 Billion DKK | -2.27% |
| 2021 FY | 58.49 Billion DKK | 12.74% |
| 2020 Q4 | 15.34 Billion DKK | 18.34% |
| 2020 Q2 | 11.39 Billion DKK | -6.49% |
| 2020 Q1 | 12.18 Billion DKK | -19.36% |
| 2020 Q3 | 12.96 Billion DKK | 13.76% |
| 2020 FY | 51.88 Billion DKK | 4.93% |
| 2019 Q4 | 15.11 Billion DKK | 23.03% |
| 2019 Q1 | 10.32 Billion DKK | -27.81% |
| 2019 Q2 | 11.73 Billion DKK | 13.71% |
| 2019 Q3 | 12.28 Billion DKK | 4.67% |
| 2019 FY | 49.45 Billion DKK | 5.29% |
| 2018 Q2 | 10.85 Billion DKK | 5.5% |
| 2018 Q4 | 14.29 Billion DKK | 23.95% |
| 2018 Q1 | 10.28 Billion DKK | -22.35% |
| 2018 FY | 46.96 Billion DKK | 4.14% |
| 2018 Q3 | 11.53 Billion DKK | 6.29% |
| 2017 Q3 | 10.29 Billion DKK | -5.03% |
| 2017 FY | 45.09 Billion DKK | -2.31% |
| 2017 Q2 | 10.84 Billion DKK | 1.23% |
| 2017 Q4 | 13.24 Billion DKK | 28.62% |
| 2017 Q1 | 10.71 Billion DKK | -20.35% |
| 2016 Q3 | 11.13 Billion DKK | 1.96% |
| 2016 Q4 | 13.44 Billion DKK | 20.82% |
| 2016 Q1 | 10.66 Billion DKK | -18.82% |
| 2016 Q2 | 10.91 Billion DKK | 2.32% |
| 2016 FY | 46.16 Billion DKK | 9.15% |
| 2015 Q4 | 13.14 Billion DKK | 19.86% |
| 2015 Q3 | 10.96 Billion DKK | 2.3% |
| 2015 Q1 | 7.46 Billion DKK | -34.65% |
| 2015 Q2 | 10.71 Billion DKK | 43.5% |
| 2015 FY | 42.29 Billion DKK | 6.4% |
| 2014 Q3 | 10.25 Billion DKK | 11.15% |
| 2014 FY | 39.75 Billion DKK | 4.78% |
| 2014 Q1 | 8.84 Billion DKK | -19.19% |
| 2014 Q2 | 9.22 Billion DKK | 4.31% |
| 2014 Q4 | 11.42 Billion DKK | 11.46% |
| 2013 Q4 | 10.94 Billion DKK | 21.68% |
| 2013 FY | 37.93 Billion DKK | 8.13% |
| 2013 Q1 | 8.81 Billion DKK | -9.41% |
| 2013 Q2 | 9.18 Billion DKK | 4.28% |
| 2013 Q3 | 8.99 Billion DKK | -2.12% |
| 2012 Q1 | 8.13 Billion DKK | -13.58% |
| 2012 Q4 | 9.72 Billion DKK | 12.04% |
| 2012 FY | 35.08 Billion DKK | 10.07% |
| 2012 Q3 | 8.68 Billion DKK | 3.47% |
| 2012 Q2 | 8.39 Billion DKK | 3.17% |
| 2011 FY | 31.87 Billion DKK | 1.14% |
| 2011 Q2 | 7.63 Billion DKK | 4.53% |
| 2011 Q3 | 7.67 Billion DKK | 0.45% |
| 2011 Q4 | 9.41 Billion DKK | 22.68% |
| 2011 Q1 | 7.3 Billion DKK | 3.6% |
| 2010 Q1 | 6.6 Billion DKK | -12.54% |
| 2010 Q2 | 7.38 Billion DKK | 11.84% |
| 2010 Q3 | 7.74 Billion DKK | 4.88% |
| 2010 Q4 | 7.05 Billion DKK | -8.94% |
| 2010 FY | 31.51 Billion DKK | 21.0% |
| 2009 FY | 26.04 Billion DKK | 12.64% |
| 2009 Q3 | 6.01 Billion DKK | -6.8% |
| 2009 Q2 | 6.45 Billion DKK | 4.48% |
| 2009 Q1 | 6.18 Billion DKK | -8.32% |
| 2009 Q4 | 7.54 Billion DKK | 25.44% |
| 2008 Q4 | 6.74 Billion DKK | 26.92% |
| 2008 FY | 23.12 Billion DKK | -0.0% |
| 2008 Q2 | 5.71 Billion DKK | 6.47% |
| 2008 Q1 | 5.36 Billion DKK | -26.05% |
| 2008 Q3 | 5.31 Billion DKK | -7.0% |
| 2007 Q2 | 5.39 Billion DKK | 4.31% |
| 2007 Q4 | 7.25 Billion DKK | 36.67% |
| 2007 FY | 23.12 Billion DKK | 15.38% |
| 2007 Q1 | 5.17 Billion DKK | -10.75% |
| 2007 Q3 | 5.3 Billion DKK | -1.66% |
| 2006 Q1 | 4.64 Billion DKK | -6.4% |
| 2006 FY | 20.04 Billion DKK | 21.68% |
| 2006 Q4 | 5.79 Billion DKK | 22.11% |
| 2006 Q2 | 4.84 Billion DKK | 4.25% |
| 2006 Q3 | 4.74 Billion DKK | -2.03% |
| 2005 Q4 | 4.96 Billion DKK | 20.38% |
| 2005 FY | 16.47 Billion DKK | 16.84% |
| 2005 Q3 | 4.12 Billion DKK | 10.79% |
| 2005 Q2 | 3.72 Billion DKK | 1.55% |
| 2005 Q1 | 3.66 Billion DKK | -6.86% |
| 2004 Q4 | 3.93 Billion DKK | 9.27% |
| 2004 FY | 14.09 Billion DKK | 10.54% |
| 2004 Q3 | 3.6 Billion DKK | 9.69% |
| 2004 Q1 | 3.17 Billion DKK | -67.29% |
| 2004 Q2 | 3.28 Billion DKK | 3.34% |
| 2003 Q1 | 972 Million DKK | 105.07% |
| 2003 Q4 | 9.71 Billion DKK | 824.38% |
| 2003 Q3 | 1.05 Billion DKK | 5.01% |
| 2003 FY | 12.75 Billion DKK | 1.58% |
| 2003 Q2 | 1 Billion DKK | 2.97% |
| 2002 Q1 | - DKK | 100.0% |
| 2002 Q2 | - DKK | 0.0% |
| 2002 Q3 | - DKK | 0.0% |
| 2002 Q4 | -19.18 Billion DKK | 0.0% |
| 2002 FY | 12.55 Billion DKK | 3.3% |
| 2001 Q1 | - DKK | 100.0% |
| 2001 FY | 12.15 Billion DKK | -0.3% |
| 2001 Q4 | -18.11 Billion DKK | 0.0% |
| 2001 Q3 | - DKK | 0.0% |
| 2001 Q2 | - DKK | 0.0% |
| 2000 Q2 | - DKK | 0.0% |
| 2000 Q3 | - DKK | 0.0% |
| 2000 FY | 12.19 Billion DKK | -0.71% |
| 2000 Q4 | -16.57 Billion DKK | 0.0% |
| 2000 Q1 | - DKK | 100.0% |
| 1999 Q2 | - DKK | 0.0% |
| 1999 Q4 | -17.32 Billion DKK | 0.0% |
| 1999 FY | 12.27 Billion DKK | 7.19% |
| 1999 Q1 | - DKK | 100.0% |
| 1999 Q3 | - DKK | 0.0% |
| 1998 Q2 | - DKK | 0.0% |
| 1998 Q1 | - DKK | 100.0% |
| 1998 Q4 | -15.84 Billion DKK | 0.0% |
| 1998 FY | 11.45 Billion DKK | 15.39% |
| 1998 Q3 | - DKK | 0.0% |
| 1997 Q4 | -14.64 Billion DKK | 0.0% |
| 1997 Q2 | - DKK | 0.0% |
| 1997 Q1 | - DKK | 100.0% |
| 1997 FY | 9.92 Billion DKK | 13.38% |
| 1997 Q3 | - DKK | 0.0% |
| 1996 FY | 8.75 Billion DKK | 9.31% |
| 1996 Q4 | -12.92 Billion DKK | 0.0% |
| 1996 Q3 | - DKK | 0.0% |
| 1996 Q2 | - DKK | 0.0% |
| 1996 Q1 | - DKK | 100.0% |
| 1995 FY | 8.01 Billion DKK | 2.12% |
| 1995 Q4 | -11.84 Billion DKK | 0.0% |
| 1995 Q3 | - DKK | 0.0% |
| 1995 Q2 | - DKK | 0.0% |
| 1995 Q1 | - DKK | 100.0% |
| 1994 Q1 | - DKK | 100.0% |
| 1994 FY | 7.84 Billion DKK | 63.63% |
| 1994 Q4 | -11.67 Billion DKK | 0.0% |
| 1994 Q3 | - DKK | 0.0% |
| 1994 Q2 | - DKK | 0.0% |
| 1993 Q4 | -11.2 Billion DKK | 0.0% |
| 1993 Q2 | - DKK | 0.0% |
| 1993 Q3 | - DKK | 0.0% |
| 1993 Q1 | - DKK | 100.0% |
| 1993 FY | 4.79 Billion DKK | -31.38% |
| 1992 Q2 | - DKK | 0.0% |
| 1992 Q1 | - DKK | 100.0% |
| 1992 Q4 | -9.51 Billion DKK | 0.0% |
| 1992 FY | 6.98 Billion DKK | 92.43% |
| 1992 Q3 | - DKK | 0.0% |
| 1991 Q4 | -8.42 Billion DKK | 0.0% |
| 1991 Q1 | - DKK | 100.0% |
| 1991 Q2 | - DKK | 0.0% |
| 1991 Q3 | - DKK | 0.0% |
| 1991 FY | 3.63 Billion DKK | 15.09% |
| 1990 Q3 | - DKK | 0.0% |
| 1990 Q4 | -7.27 Billion DKK | 0.0% |
| 1990 Q2 | - DKK | 0.0% |
| 1990 FY | 3.15 Billion DKK | 12.48% |
| 1990 Q1 | - DKK | 100.0% |
| 1989 Q3 | - DKK | 0.0% |
| 1989 Q1 | - DKK | 100.0% |
| 1989 Q2 | - DKK | 0.0% |
| 1989 Q4 | -6.56 Billion DKK | 0.0% |
| 1989 FY | 2.8 Billion DKK | 41.85% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -2458496.489% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -108123.771% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -35885520.84% |
| SQZ Biotechnologies Company | 85.61 Million USD | -109597.614% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -3220559.515% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -317708.683% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -252001.21% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -6253449.673% |
| Marizyme, Inc. | 19.23 Million USD | -488064.346% |
| Genus plc | 147.7 Million USD | -63489.709% |
| Pharming Group N.V. | 225.49 Million USD | -41552.217% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -4584357.011% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -7000932.392% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1126198.117% |
| ContraFect Corporation | 56.88 Million USD | -164996.943% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -6351336.887% |
| IMV Inc. | 37.7 Million USD | -248969.094% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -3365849.232% |
| ONE Bio Corp. | 6.44 Million USD | -1457435.291% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -109181.517% |
| Mesoblast Limited | 5.9 Million USD | -1591258.861% |
| MultiCell Technologies, Inc. | 567.42 USD | -16552465445.804% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -379920.231% |
| Genscript Biotech Corporation | 825.34 Million USD | -11279.74% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -24109293.53% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -3574446.664% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1909693.85% |
| Biomind Labs Inc. | 994.18 Thousand USD | -9447063.598% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -5337353.784% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1397961.779% |
| Skye Bioscience, Inc. | 13.54 Million USD | -693176.644% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -5037633.926% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1069719.987% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 375688100.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -2130292.1% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1862676.287% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -586537.162% |
| Accustem Sciences Inc. | 3.74 Million USD | -2506880.666% |
| EV Biologics, Inc. | 531.96 Thousand USD | -17655672.405% |
| Q BioMed Inc. | 3.43 Million USD | -2732869.643% |
| GB Sciences, Inc. | 1.42 Million USD | -6611755.328% |
| Alpha Cognition Inc. | 9.7 Million USD | -967609.264% |
| CSL Limited | 3.44 Billion USD | -2623.166% |
| Agentix Corp. | 1.37 Million USD | -6846744.483% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -94455.359% |
| Enzolytics Inc. | 2.17 Million USD | -4309223.163% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | -738745.186% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -2572607.15% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -5118000.153% |
| argenx SE | 1.53 Billion USD | -6024.562% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -163413.231% |
| HST Global, Inc. | 140.9 Thousand USD | -66655211.659% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -8996260.153% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -8349190.165% |
| Halberd Corporation | 74.84 Thousand USD | -125493606.742% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -3905287.84% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -2758272.372% |
| Zenith Capital Corp. | 8.94 Million USD | -1050129.23% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -5946758.053% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -3825149.448% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1284696.281% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -54762040.762% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -4889363.618% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -539130833.93% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -3807403.037% |
| Helix BioMedix, Inc. | 1.97 Million USD | -4762596.789% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -864186.372% |
| Kadimastem Ltd | 2.41 Million USD | -3896897.318% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -408704.394% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -51751835.422% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -7032985.199% |
| LadRx Corporation | 3.81 Million USD | -2463886.089% |
| Cell Source, Inc. | 4.32 Million USD | -2171333.222% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -22605615.331% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -10170011.856% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -10170011.856% |
| Affymax, Inc. | 39.38 Million USD | -238365.445% |
| Mobile Lads Corp. | 554.54 Thousand USD | -16936637.439% |
| Itoco Inc. | 919.14 Thousand USD | -10218331.735% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2215870.408% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -8393286.953% |
| International Stem Cell Corporation | 5.27 Million USD | -1781763.024% |
| CytoDyn Inc. | 18.05 Million USD | -520012.969% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -373165301.883% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -42676587.356% |
| Qrons Inc. | 643.67 Thousand USD | -14591379.888% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -6615094.338% |
| SYBLEU INC | 160.87 Thousand USD | -58381510.682% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -4211877.421% |
| Rebus Holdings, Inc. | 664 Thousand USD | -14144779.518% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -5170905.109% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -178416373.538% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -461691882.5% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -258880.864% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -5804720.766% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -12763902.8% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -3018929.251% |
| Neutra Corp. | 243.82 Thousand USD | -38520782.123% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -537919.133% |
| PureTech Health plc | 144.59 Million USD | -64854.321% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -458282.203% |
| IXICO plc | 4.7 Million USD | -1995268.6% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1067559.429% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -79665.261% |
| CSL Limited | 3.89 Billion USD | -2312.587% |
| Cellectis S.A. | 97.32 Million USD | -96408.426% |